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ANSWERS TO SELF-ASSESSMENT QUESTIONS
1. Which of the following best describes potential reasons for false-negative mo-
lecular testing for SARS-CoV-2?
a. Analytical errors involving improper transport and storage of specimens
b. Preanalytical errors stemming from the limited sensitivity of the molecular
test
c. Analytical errors due to incorrect sampling by the clinician obtaining the
specimen for testing
d. Preanalytical errors related to interfering substances inhibiting molecular
testing
Answer: d. Possible preanalytical issues related to false-negative molecular test-
ing for SARS-CoV-2 include the presence of interfering substances such as blood
and intranasal medications. Additional preanalytical causes for false-negative
results include inadequate specimen collection, improper transport and/or stor-
age of specimens, virus not being present at the site of collection secondary to
biology, and testing too early or late in the course of disease. Analytical consid-
erations include the use of assays with poor sensitivity, poor assay performance,
and instrument errors. Choices a and c describe preanalytical errors, while choice
b relates to an analytical issue.
2. A patient in acute respiratory distress is admitted to the ICU, with strong clinical
suspicion of SARS-CoV-2 infection. Initial molecular testing on admission is
negative for SARS-CoV-2 RNA. What should additional clinical management of
this patient include?
a. Assume the patient is negative to avoid overuse of personal protective
equipment
b. Test lower respiratory tract samples if available to help confirm the diag-
nosis of COVID-19
c. Perform chest X-ray to confirm negative result and definitively rule out
COVID-19
d. Perform antibody testing to confirm negative result and definitively rule
out COVID-19
Answer: b. As described in this case presentation, the patient has a high pretest
probability for infection. As such, alternate specimen types should be considered
for diagnosis. The nasopharyngeal swab should not be considered the “gold
standard” for diagnostic purposes, as the virus may not always be present at that
site in COVID-19 patients. Patients who are symptomatic and suspected of having
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COVID-19 should be immediately placed under appropriate infection control
settings, regardless of test results (choice a). Chest X-ray has been shown to be
positive for characteristic ground-glass opacities in certain patients with pulmo-
nary involvement though this cannot be used alone to rule out disease (choice
c). Finally, serology can take up to 14 days to become positive and therefore
cannot be used to rule out COVID-19 (choice d).
3. Which of the following described processes would result in the best sampling of
the nasopharynx for COVID-19 testing?
a. A single flocked swab inserted into the nares to a depth equal to the
distance from the nares to the opening of the ears
b. A single flocked swab inserted into the oral cavity to the back of the throat
past the palatine tonsils
c. A single flocked swab inserted 3 cm deep into the right nares and then
reinserted 3 cm deep into the left nares
d. A single flocked swab inserted into the nares to a depth equal to the
distance from the nares to the eyes
Answer: a. Proper sampling of the nasopharynx is essential when submitting naso-
pharyngeal swabs for SARS-CoV-2 testing. This requires insertion of a single flocked
swab into the nares to a depth equal to the distance from the nares to the opening
of the ears. This process often causes some patient discomfort though is necessary
to test for viruses that replicate in the nasopharynx. Swabs not inserted as far into the
nares as recommended should be regarded as nasal swabs. Testing of nasal swabs
is offered under the EUA of select manufacturers. Choice b refers to the process of
collecting an oropharyngeal swab, which is also offered by some manufacturers as
an acceptable specimen type. More data are needed to determine the overall
suitability of these specimen types compared to others for SARS-CoV2 testing.
TAKE-HOME POINTS
● SARS-CoV-2 is a novel coronavirus, responsible for the COVID-19 pandemic.
Infection with SARS-CoV-2 can result in a spectrum of symptoms ranging from
mild shortness of breath and fever to respiratory failure and death. The
diagnosis of SARS-CoV-2 has relied almost exclusively on molecular testing on
nasopharyngeal (NP) swabs, the most commonly submitted specimen type.
● With the increasing availability of various SARS-CoV-2 assays, there is an
abundance of options with a lack of clinical performance data. Appropriate
validation of molecular tests offered by the lab for SARS-CoV-2 diagnostics is
essential prior to clinical use.
● Multiple explanations for false-negative results have been proposed. The diag-
nostic performance of the assay is commonly suspected as a cause of erroneous
results; however, this encompasses only one of many possibilities, including
preanalytical, analytical, and postanalytical errors.
● The timing of specimen collection and viral infection kinetics influence the
clinical sensitivity of SARS-CoV-2 molecular detection. Studies have demon-
strated great variability in the presence of virus in the upper respiratory tract
during the course of infection. While viral loads are highest earlier in the disease
course, it is not clear why in certain individuals virus is detected only in
locations other than the upper airways.
● The reliance on a single test from a single specimen type to rule out SARS-
CoV-2 can be problematic. Clinical suspicion and epidemiological information
should not be ignored due to a negative molecular test result.
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